Abstract
AbstractThromboembolic complications are increasing in children and the use of anticoagulation has seen a dramatic increase despite the lack of randomized clinical trials. The most widely used agents in children are heparin, low-molecular-weight heparins (LMWH), and warfarin. These agents, however, have significant limitations that are exaggerated in children. Novel anticoagulants such as direct thrombin inhibitors and the selective factor Xa inhibitor, fondaparinux, have been approved for use in adults and have properties that suggest they may be safer and more efficacious than the standard agents; however, until recently, publications using these agents in children were limited to case reports. Recently, clinical trials for two direct thrombin inhibitors, bivalirudin and argatroban, have been completed and a clinical trial of fondaparinux is under way. This review will compare the standard agents with the novel agents and briefly review the results of the clinical trials.
Publisher
American Society of Hematology
Reference45 articles.
1. Hutinel V. Contribution a l’etude des troubles de la circulation veineuse chez l’enfant et en particulier chez le noveau ne. Paris: V. Adrien Delahaye et Co; 1877.
2. Bartolozzi G, Guazzelli C. [Two cases of septic thrombosis of the cavernous sinus cured by antibiotics and heparin.] Riv Clin Pediatr. 1954;54:429–439.
3. Carpentieri U, Nghiem QX, Harris LC. Clinical experience with an oral anticoagulant in children. Arch Dis Child. 1976;51:445–448.
4. Massicotte P, Adams M, Mazinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr. 1996;128:313–318.
5. Ranze O, Ranze P, Magnani HN, Greinacher A. Heparin-induced thrombocytopenia in paediatric patients—a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr. 1999;158:S130–S133.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献